Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

The Basis for Strain-Dependent Rat Aldehyde Dehydrogenase 1A7 (ALDH1A7) Gene Expression

Katerina Touloupi, Jenni Küblbeck, Angeliki Magklara, Ferdinand Molnár, Mika Reinisalo, Maria Konstandi, Paavo Honkakoski and Periklis Pappas
Molecular Pharmacology November 2019, 96 (5) 655-663; DOI: https://doi.org/10.1124/mol.119.117424
Katerina Touloupi
Departments of Pharmacology (K.T., M.K., P.P.) and Clinical Chemistry (A.M.), Faculty of Medicine, School of Health Sciences, University of Ioannina, and Department of Biomedical Research, Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology (A.M.), Ioannina, Greece; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland (J.K., F.M., M.R., P.H.);Department of Biology, School of Science and Technology, Nazarbayev University, Nur-Sultan City, Kazakhstan (F.M.); Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenni Küblbeck
Departments of Pharmacology (K.T., M.K., P.P.) and Clinical Chemistry (A.M.), Faculty of Medicine, School of Health Sciences, University of Ioannina, and Department of Biomedical Research, Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology (A.M.), Ioannina, Greece; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland (J.K., F.M., M.R., P.H.);Department of Biology, School of Science and Technology, Nazarbayev University, Nur-Sultan City, Kazakhstan (F.M.); Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jenni Küblbeck
Angeliki Magklara
Departments of Pharmacology (K.T., M.K., P.P.) and Clinical Chemistry (A.M.), Faculty of Medicine, School of Health Sciences, University of Ioannina, and Department of Biomedical Research, Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology (A.M.), Ioannina, Greece; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland (J.K., F.M., M.R., P.H.);Department of Biology, School of Science and Technology, Nazarbayev University, Nur-Sultan City, Kazakhstan (F.M.); Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angeliki Magklara
Ferdinand Molnár
Departments of Pharmacology (K.T., M.K., P.P.) and Clinical Chemistry (A.M.), Faculty of Medicine, School of Health Sciences, University of Ioannina, and Department of Biomedical Research, Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology (A.M.), Ioannina, Greece; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland (J.K., F.M., M.R., P.H.);Department of Biology, School of Science and Technology, Nazarbayev University, Nur-Sultan City, Kazakhstan (F.M.); Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ferdinand Molnár
Mika Reinisalo
Departments of Pharmacology (K.T., M.K., P.P.) and Clinical Chemistry (A.M.), Faculty of Medicine, School of Health Sciences, University of Ioannina, and Department of Biomedical Research, Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology (A.M.), Ioannina, Greece; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland (J.K., F.M., M.R., P.H.);Department of Biology, School of Science and Technology, Nazarbayev University, Nur-Sultan City, Kazakhstan (F.M.); Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mika Reinisalo
Maria Konstandi
Departments of Pharmacology (K.T., M.K., P.P.) and Clinical Chemistry (A.M.), Faculty of Medicine, School of Health Sciences, University of Ioannina, and Department of Biomedical Research, Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology (A.M.), Ioannina, Greece; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland (J.K., F.M., M.R., P.H.);Department of Biology, School of Science and Technology, Nazarbayev University, Nur-Sultan City, Kazakhstan (F.M.); Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maria Konstandi
Paavo Honkakoski
Departments of Pharmacology (K.T., M.K., P.P.) and Clinical Chemistry (A.M.), Faculty of Medicine, School of Health Sciences, University of Ioannina, and Department of Biomedical Research, Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology (A.M.), Ioannina, Greece; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland (J.K., F.M., M.R., P.H.);Department of Biology, School of Science and Technology, Nazarbayev University, Nur-Sultan City, Kazakhstan (F.M.); Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paavo Honkakoski
  • For correspondence: phonka@email.unc.edu
Periklis Pappas
Departments of Pharmacology (K.T., M.K., P.P.) and Clinical Chemistry (A.M.), Faculty of Medicine, School of Health Sciences, University of Ioannina, and Department of Biomedical Research, Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology (A.M.), Ioannina, Greece; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland (J.K., F.M., M.R., P.H.);Department of Biology, School of Science and Technology, Nazarbayev University, Nur-Sultan City, Kazakhstan (F.M.); Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Periklis Pappas
  • For correspondence: ppappas@cc.uoi.gr
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Aldehyde hydrogenases (ALDHs) belong to a large gene family involved in oxidation of both endogenous and exogenous compounds in mammalian tissues. Among ALDHs, the rat ALDH1A7 gene displays a curious strain dependence in phenobarbital (PB)-induced hepatic expression: the responsive RR strains exhibit induction of both ALDH1A7 and CYP2B mRNAs and activities, whereas the nonresponsive rr strains show induction of CYP2B only. Here, we investigated the responsiveness of ALDH1A1, ALDH1A7, CYP2B1, and CYP3A23 genes to prototypical P450 inducers, expression of nuclear receptors CAR and pregnane X receptor, and structure of the ALDH1A7 promoter in both rat strains. ALDH1A7 mRNA, associated protein and activity were strongly induced by PB and modestly induced by pregnenolone 16α-carbonitrile in the RR strain but negligibly in the rr strain, whereas induction of ALDH1A1 and P450 mRNAs was similar between the strains. Reporter gene and chromatin immunoprecipitation assays indicated that the loss of ALDH1A7 inducibility in the rr strain is profoundly linked with a 16-base pair deletion in the proximal promoter and inability of the upstream DNA sequences to recruit constitutive androstane receptor-retinoid X receptor heterodimers.

SIGNIFICANCE STATEMENT Genetic variation in rat ALDH1A7 promoter sequences underlie the large strain-dependent differences in expression and inducibility by phenobarbital of the aldehyde dehydrogenase activity. This finding has implications for the design and interpretation of pharmacological and toxicological studies on the effects and disposition of aldehydes.

Introduction

The aldehyde dehydrogenases (ALDHs) are present in all taxonomic groups, and they are involved in the irreversible oxidation of endogenous and exogenous aldehydes (Sophos et al., 2001). Their functionality extends far beyond enzymatic detoxification processes because they participate in the growth, differentiation, and survival of cells and in the synthesis of biomolecules, such as retinoic acid, betaine, and γ-aminobutyric acid. ALDHs may also serve as biomarkers for certain cancer types and Parkinson disease (Westerlund et al., 2005; Jackson et al., 2011). Among the 21 genes of the rat ALDH gene superfamily (Jackson et al., 2011), the cytosolic isoforms ALDH1A1, 2, 3, and 7 are involved in the metabolism of, for example, aliphatic aldehydes and retinal and cyclophosphamide (Kathmann et al., 2000; Alnouti and Klaassen, 2008). Among these isoforms, rat ALDH1A1 and ALDH1A7 are highly homologous and display similar tissue-expression patterns, with high mRNA levels reported in the liver, lung, and kidneys (Marselos et al., 1987; Hsu et al., 1999; Kathmann et al., 2000). Moreover, hepatic expression of rat ALDH1A1 and 1A7 isozymes is induced by phenobarbital (PB), a prototypical inducer of several cytochrome P450 (P450) enzymes.

In rodents, PB is known to induce many P4540s and other drug-metabolizing enzymes and transporters via the nuclear receptor (NR) constitutive androstane receptor (CAR), whereas many drugs induce their expression by activation of the pregnane X receptor (PXR) (Honkakoski and Negishi, 2000; Chai et al., 2013). Others reported that selective CAR or PXR activators modestly increased (2- to 3.5-fold) Aldh1a1 and Aldh1a7 gene expression in the livers of wild-type mice but not in mice with disrupted Car or Pxr genes, whereas the expression of other Aldh family members was not appreciably affected by NR activation (Aleksunes and Klaassen, 2012). These findings indicate that the key NRs regulating drug-metabolizing enzymes are involved in the regulation of cytosolic ALDH1A isoforms.

The induction of cytosolic ALDH by PB has been investigated because of genetic strain differences in specific Long-Evans rat strains (Deitrich, 1971; Dunn et al., 1989; Kathmann et al., 2000). The extent of PB-elicited induction of rat liver cytosolic ALDH activity appears to be regulated by two alleles of a single autosomal locus. The dominant allele R confers responsiveness to PB, whereas the recessive allele r is nonresponsive. Homozygous responders (RR) exhibit maximal ALDH induction by PB, heterozygous rats (Rr) display a moderate induction and homozygous nonresponders (rr) show only a small, if any, increase of ALDH activity. Constitutive ALDH mRNA expression (initially termed ALDH-PB, now recognized as ALDH1A7) is detectable in both strains, but it is strongly inducible in only the RR rats. Interestingly, the expression of other PB-inducible enzymes, such as CYP2B1 and CYP2B2, reached similar levels in these strains after exposure to PB (Dunn et al., 1989; Pappas et al., 2001); however, the molecular basis for this ALDH-selective disparity in induction by PB remains unexplored to this day. To investigate this problem, we used the Wistar/Af/Han/Mol/Kuo/Io rat strain that is currently bred and maintained at University of Ioannina. This Wistar rat strain also exhibits discordant patterns of ALDH1A expression that are similar to the Long-Evans rat strains (Pappas et al., 1998; Pappas et al., 2001). The basal ALDH1A activity is ∼2-fold greater, and its PB inducibility is markedly higher in the RR strain (>15-fold vs. 2.5-fold) compared with the rr strain. Here, we cloned and characterized ALDH1A7 from both Wistar rat strains to identify the defect in PB induction and investigated its regulation by CAR and PXR.

Materials and Methods

Chemicals.

Phenobarbital (PB) and mifepristone (RU486) were from Sigma-Aldrich (St. Louis, MO). Pregnenolone 16α-carbonitrile (PCN) was bought from SantaCruz Biotechnology (Heidelberg, Germany). Synthesis of the mouse CAR agonist 1,4-bis[(3,5-dichloropyridyloxy)]benzene (TCPOBOP) has been previously described (Honkakoski et al., 1996). All other chemicals were of the highest analytical grade.

Experimental Animal Model and Treatments.

Wistar/Af/Han/Mol/Kuo/Io male rats (aged 3–5 months and weighing 170–230 g) were isolated and reproduced by inbreeding at the University of Ioannina, creating substrains that are responsive (RR) and nonresponsive (rr) to PB (Marselos, 1976). All animals were treated according to the European Communities Council Directive (86/609/EEC) and housed in groups of two or three in plastic cages under constant environmental conditions on a 12-hour light/dark cycle at ambient temperature and provided with chow and tap water ad libitum. All in vivo experiments were reviewed and approved by the Institutional Animal Care and Use Committee of the Medical School at the University of Ioannina (license number EL33BIO-exp01). For the multiple-dose study, 3-month old male rats (four per group) were injected intraperitoneally with selective activators of CAR and PXR (Stanley et al., 2006): three doses of PB (80 mg/kg, dissolved in saline), four doses of PCN (50 mg/kg, dissolved in olive oil), or the corresponding vehicle. Animals were sacrificed by carbon asphyxiation 6 hours after the PB injection. For the time-response study, 3-month-old male rats were divided into groups of four and treated with a single dose of PB (80 mg/kg), PCN (50 mg/kg), or vehicle. Animals were sacrificed by carbon asphyxiation after 6, 12, or 24 hours of PB or PCN injection.

Total RNA Isolation, cDNA Synthesis, and Quantitative Reverse Transcription-Polymerase Chain Reaction.

After decapitation, small liver samples were stored in RNAlater at −80°C until use. Total RNA was isolated with the Nucleospin RNA II total RNA isolation kit (Macherey-Nagel, Düren, Germany). RNA samples (1 μg) served as templates for cDNA synthesis using Quanti-Tect Reverse Transcription kit (Qiagen, Hilden, Germany). Analysis of liver mRNA levels was performed with real-time reverse transcription polymerase chain reaction (RT-PCR), based on the TaqMan protocol, by use of KAPA Probe Fast qPCR Master Mix (KAPA Biosystems, Wilmington, MA) and TaqMan Gene Expression Assay primers for rat ALDH1A1, ALDH1A7, CAR, PXR, CYP2B1, CYP3A23, and β-actin genes (Applied Biosystems, Foster City, CA). Amplification reactions (two replicate reactions per sample) were performed on the CFX96 real-time system and the C1000 thermal cycler (Bio-Rad Laboratories, Hercules, CA). Gene-expression analysis was performed by the ΔΔCt method (Müller et al., 2002), normalized for β-actin mRNA levels and expressed as mean ± S.D. (n = 4) relative to the value of control RR strain sample set as 1.

Protein Extraction and Western Blotting.

Liver samples were placed into ice-cold PBS and then homogenized either in hypotonic buffer (10 mM Hepes pH 7.9, 1.5 mM MgCl2, 5 mM KCl with 0.1% NP-40) for cytosolic proteins, in high-salt extraction buffer (20 mM Hepes pH 7.9, 25% glycerol, 450 mM KCl, 1 mM EDTA) for nuclear proteins or in RIPA buffer [50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 1% Na-deoxycholate, 0.1% sodium dodecyl sulfate (SDS)] for total proteins. Protease and phosphatase inhibitors [1 μg/ml aprotinin, 1 μg/ml leupeptin, 50 μg/ml phenylmethyl sulfonyl fluoride, 50 μg/ml Na3VO4, 1 mM dithiothreitol] were added to these buffers just before use. Proteins (50–100 μg) were separated in 7.5%–12% SDS-PAGE and transferred onto a nitrocellulose membrane (Protran; Schleicher & Schuell, Dassel, Germany). Membranes were first blocked in 5% milk in Tris-buffered saline and then incubated with anti-rabbit ALDH1/2 antibody (1:500; sc-50385; Santa Cruz; likely to detect at least ALDH1A1 and 1A7 isoforms that have similar molecular masses of 54 kDa), anti-mouse CAR (1:1000; PP-N4111-00; Perseus Proteomics; Tokyo, Japan), anti-mouse PXR (1:1000; PP-H4417-00; Perseus Proteomics). Goat anti-rabbit (sc-2004; Santa Cruz) and goat anti-mouse (sc-2005; Santa Cruz) horseradish peroxidase-conjugated antibodies were used as secondary antibodies at 1:5000 dilution. Immunodetection of bands was based on enhanced chemiluminescence kit (GE Healthcare, Little Chalfont, UK). Three independent sets of control, PB- or PCN-exposed rats were analyzed. Typical results from one set are shown in Figs. 1 and 2, and results of the remaining two sets are shown in the Supplemental Figs. 2 and 3.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Strain-dependent expression and inducibility of ALDH1A isoforms. Normalized expression of ALDH1A7 (A) and ALDH1A1 (B) mRNA in control, PB-, or PCN-treated RR and rr rat livers. Levels are expressed as scatter plots and means ± S.D. from four animals, each sample with two technical replicates. Cytosolic and total protein levels of ALDH1 protein (C) and activity (D) in control, PB-, or PCN-treated RR and rr rat livers. Statistically significant differences (P < 0.05) compared with the respective control group or between the strains are marked by * and # signs, respectively. The data in (A, B, and D) are also shown relative to the control RR values, set at 1.0, and expressed as means ± S.D. of -fold change below the x-axis.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Similar expression of CYP2Bs and NRs in both rat substrains. Normalized expression of CYP2B1 (A) and CYP3A23 (B) mRNA in control, PB-, or PCN-treated RR and rr rat livers. (C) Comparison of hepatic CAR and PXR mRNA expression between control rat strains. The ratio of target gene to β-actin mRNA expression (y-axis) are shown as scatter plots and means ± S.D. from four animals, each sample with two technical replicates. These normalized levels are also depicted as relative to the mean ± S.D. of the control RR strain, set at 1.0, and indicated below the x-axis. Statistically significant differences (P < 0.05) compared with the respective control group or between the strains are marked by * and # signs, respectively. (D) Expression of CAR and PXR proteins in control, PB- or PCN-treated RR and rr rat livers.

ALDH1 Activity Assay.

Liver samples were homogenized in ice-cold sucrose and centrifuged at 20, 000g for 30 minutes. Supernatants were used for the kinetic measurement of ALDH activity with propionaldehyde as substrate as described (Vasiliou and Marselos, 1989). This activity cannot distinguish between the cytosolic ALDH isoforms 1A1, 2, 3 and 7. Determination of the protein concentration was carried out according to the Lowry method (Lowry et al., 1951). The specific activities are expressed as mean ± S.D. of four animals per group.

Cloning of the ALDH1A7 Promoter and Reporter Constructs.

Genomic DNA was isolated from liver tissue (25 mg) from 3-month-old male RR and rr rats according to the protocol of NucleoSpin tissue kit (Macherey-Nagel). The amplification of ∼10 kilobase pair (kbp) fragments of ALDH1A7 promoters (Rnor 5.0; Chr1: 247, 897, 931-247, 887, 931; reverse complement) from genomic DNA, and sequencing was done by Epoch Life Science Inc. (Missouri City, TX). The RR and rr promoter sequences have been submitted to the NCBI GenBank with accession numbers MK814117 and MK814118, respectively. The fragments were inserted into pGL3-Basic plasmid vectors (Promega, Madison, WI) at KpnI and XhoI restriction sites. Sequential deletion fragments of ALDH1A7 promoters were generated by amplification with Phusion high-fidelity DNA polymerase (Finnzymes, Espoo, Finland) or KAPA HiFi (hot start) DNA polymerase (KAPA Biosystems) and forward and reverse primers (Oligomer, Helsinki, Finland) shown in Supplemental Table 1. The deletion fragments were cloned into pGL3-Basic plasmid vectors and competent Escherichia coli bacteria (XL-10 or DH5α) were transformed with the constructs. Colonies were screened by colony PCR using DreamTaq DNA polymerase (ThermoScientific, Vantaa, Finland). Plasmid DNAs from positive colonies were purified with QIAprep Spin Miniprep kit (Qiagen) and verified by dideoxy sequencing (DNA Analysis Facility, Yale University, New Haven, CT).

Reporter Gene Assays.

The full-length mouse CAR and PXR constructs (Mäkinen et al., 2002) and the respective reporters (for CAR, PBREM-tk-luc; for PXR, XREM-3A4-luc) (Goodwin et al., 1999; Honkakoski et al., 2001) have been described earlier. C3A hepatoma cells were seeded on 48-well plates (∼180,000 cells/cm2). The cells were transfected with the calcium phosphate method (Küblbeck et al., 2008) with the appropriate combinations of the following three plasmids: one of the NR expression plasmids [full-length CAR, full-length PXR, or the empty expression vector (100 ng/well)], one of the reporter plasmids [individual ALDH1A7 promoter construct, negative control pGL3-basic plasmid, positive control PBREM-tk-luc or XREM-3A4-luc reporters (450 ng/well)], plus the transfection control plasmid pCMVβ (900 ng/well). Untransfected cells served as blank samples for reporter enzyme assays. After transfection for 4 hours, the medium was removed and fresh DMEM supplemented with 5% delipidated serum (HyClone, Logan, UT) was added onto the transfected cells. The added medium also contained either the vehicle (DMSO, 0.1%) or activating NR ligands (1 μM TCPOBOP for mouse CAR; 10 μM RU486 for mouse PXR). After treatment with chemicals for 24 hours, the cells were lysed and assayed for luciferase and β-galactosidase activities as before (Honkakoski et al., 2001). Blank-subtracted luciferase activities were normalized, that is, divided, by blank-subtracted β-galactosidase activities and expressed relative to the empty pGL3-Basic reporter set at 1. Data are mean ± S.D. from three independent transfections.

Chromatin Immunoprecipitation Assay.

Chromatin immunoprecipitation (ChIP) assays were performed according to Magklara and Smith (2009) with some modifications. Male 3-month-old RR and rr rats (two per condition) were injected with PB (80 mg/kg) or saline and killed by carbon dioxide asphyxiation 3 hours later. Liver samples (80–100 mg) were fixed in 1% formaldehyde solution, and the cross-linking reaction was quenched by incubating the samples in 0.125 M glycine. The samples were then homogenized in sucrose buffer (0.3 M sucrose, 15 mM NaCl, 5 mM MgCl2, 0.1 mM EDTA, 15 mM Tris-HCl, 0.5 mM dithiothreitol, 0.1 mM phenylmethyl sulfonyl fluoride) and centrifuged. The pelleted homogenates were resuspended in lysis buffer (50 mM Tris-HCl pH 8, 10 mM EDTA, 1% SDS) and incubated on ice for 10 minutes. Lysates were centrifuged and resuspended in sonication buffer (50 mM Hepes pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton-X, 0.1% Na-deoxycholate, 0.1% SDS). After sonication (80% power, 4 × 20 seconds with 1-minute cooling intervals; Misonix sonicator, Misonix, Inc., Farmingdale, NY), the DNA was sheared to an average length of 300–800 bp. The supernatants were diluted in ChIP dilution buffer (1.2 mM EDTA, 167 mM NaCl, 16.7 mM Tris-HCl pH 8, 1.1% Triton X-100, 0.01% SDS) and precleared with Protein A/G PLUS-agarose beads (sc-2003; Santa Cruz) at 4°C. Then, the beads were removed and 1/10 of the genomic DNA was retained as input control for quantitative PCR analysis. Precleared chromatin samples were incubated at 4°C overnight, with the addition of 5 μg polymerase II antibody (sc-899; Santa Cruz) or 5 μg of retinoid X receptor-α (RXRα) antibody (sc-553; Santa Cruz). On the following day, protein-DNA complexes were precipitated after a 3-hour incubation with A/G beads. The beads were washed successively with low-salt buffer (2 mM EDTA, 20 mM Tris-HCl pH 8, 0.1% SDS, 1% Triton X-100, 150 mM NaCl), high-salt buffer (low-salt buffer with 500 mM NaCl), LiCl wash buffer (1 mM EDTA, 10 mM Tris-HCl pH 8, 1% Nonidet P-40, 1% Na-deoxycholate, 0.25 M LiCl) and twice with TE buffer (1 mM EDTA, 10 mM Tris-HCl pH 8). All buffers contained 1× protease inhibitor cocktail (P-27140; Sigma). After the two elution steps, the eluates and inputs were incubated with 5 M NaCl in 65°C overnight to reverse the DNA/protein crosslinks. After treatment with proteinase K (2 hours at 55°C), DNA was purified by phenol–chloroform-isoamyl alcohol extraction and ethanol precipitation. The DNA samples were analyzed by quantitative PCR in duplicate using KAPA SYBR FAST qPCR Master Mix (KK4601) and calculated by the 2^−ΔCt method after correcting for the IgG-negative control. The PCR primers used were synthesized by Eurofins Genomics (Ebersberg, Germany) and listed in the Supplemental Table 2.

Statistical Analysis.

Differences between groups were evaluated by analysis of variance and Bonferroni’s multiple comparison test. The main comparisons were between the strains and between the control and inducer groups. Probability values P < 0.05 were considered statistically significant, but they are shown for descriptive purposes, not for hypothesis testing.

Results

Differential Expression of ALDH1A7 in RR and rr Rat Strains.

Hepatic expression of ALDH1A1 and ALDH1A7 genes was studied after multiple doses of PB and PCN. Figure 1A shows that constitutive expression of rat ALDH1A7 mRNA was higher in the RR but still detectable in the rr rat strain. ALDH1A7 mRNA levels were induced more than 100-fold by PB and almost 20-fold by PCN only in the responsive RR strain, whereas no equivalent induction was detected in the rr strain. On the other hand, constitutive rat ALDH1A1 mRNA expression was only slightly higher in the rr strain whereas the induction of ALDH1A1 mRNA was comparable, reaching 4- to 10-fold by PB and 4- to 6-fold by PCN in both strains (Fig. 1B). Western blotting of cytosolic and total protein extracts (Fig. 1C; Supplemental Fig. 2) indicated low expression of ALDH1 proteins in control animals, whereas high expression levels were seen in PB-treated and moderate induction in PCN-treated RR rats only. It should be noted that the antibody used in Western blotting was the only one commercially available, and it does not distinguish between various ALDH1A isoforms. The ALDH1 (propionaldehyde/NAD+) activity (Fig. 1D), catalyzed by all ALDH1A isozymes (Lindahl, 1992; Alnouti and Klaassen, 2008), displayed similar basal levels between the strains. It was elevated 3.5- and 4.5-fold by PB and PCN in the responsive RR rats, but it was only marginally elevated in the rr strain. These findings confirmed earlier reports on PB induction of both ALDH1A1 and 1A7 isoforms and the strain difference in ALDH1A7 inducibility by PB (Dunn et al., 1989; Pappas et al., 2001).

Expression of Inducible P450s and NRs in RR and rr Rats.

Similar analyses revealed that hepatic transcripts of the main rat PB- and PCN-inducible CYP2B1 and CYP3A23 genes (Honkakoski and Negishi, 2000; Stanley et al., 2006) are detected in the untreated RR and rr animals at similar levels and are similarly induced by PB and PCN (Fig. 2, A and B). PB, an activator of rodent CAR, preferentially induced CYP2B1 over CYP3A23 mRNA. PCN, a ligand of rodent PXR, induced CYP3A23 over CYP2B1 mRNA expression, as expected. Furthermore, there was maximally only about a 2-fold change in the Ct values of β-actin mRNA between the control and induced groups (Supplemental Table 5), indicating that the observed strain differences and induction responses are not due to changes in the expression of the control gene used in normalization.

Furthermore, the expression of rat CAR and PXR mRNA (Fig. 2C) and the protein levels in total liver extracts (Fig. 2D; Supplemental Fig. 3) were also comparable. In time-course experiments, induction of ALDH1A1, ALDH1A7 (RR strain only), CYP2B1, and CYP3A23 mRNAs was clearly detectable 6 hours after PB or PCN injection, indicating a rapid transcriptional response (Supplemental Figs. 4 and 5). These results show that CAR and PXR receptors are present in both rat strains and function appropriately as regulators of ALDH1A, CYP2B, and CYP3A genes.

Comparison of ALDH1A7 Promoter Sequences in RR and rr Rats.

The remarkable absence of ALDH1A7 induction by PB, but normal expression and functionality of NRs in rr rats, suggested that the genetic difference in inducibility between the RR and rr strains may be related to changes in DNA sequences of their respective ALDH1A7 genes. To study this hypothesis, genomic DNA from both strains was isolated, and ∼10 kbp of ALDH1A7 promoter fragments were amplified and sequenced. Alignment of the two promoter sequences showed that they are 97.6% identical (Supplemental Fig. 1), with the ALDH1A7 sequence from the rr strain matching completely the available rat ALDH1A7 sequence for Rattus norvegicus (ALDH1A7; Chr1:247, 847, 960-247, 887, 931 in the Rnor 5.0 assembly). Detailed comparison of the two ALDH1A7 promoter sequences indicated that there were two larger deletions in the rr strain compared with the RR strain: one was a 165-bp region at ∼2200 bp upstream of the transcription start site (TSS), missing in the rr strain. Another deletion (16 bp) occurred just upstream of the TATA box at −50/−34 bp. In addition, several small deletions and point mutations were present (Supplemental Fig. 1). With regard to transcription factor (TF) sites that could influence PB or PCN inducibility and/or hepatic expression of ALDH1A7 mRNA, we identified binding sites for CAR/RXRα sites, CCAAT box and DR3, DR4 and ER6 elements, which are shown in Supplemental Tables 3 and 4, respectively. None, however, showed a major difference between the RR and rr strains, and none was present in the above two deletion regions.

Activity of the Full-Length ALDH1A7 Promoters from RR and rr Rats.

The 10-kbp ALDH1A7 gene promoters were inserted into the pGL3-Basic reporter plasmid, co-transfected with mouse NR expression vectors into C3A hepatoma cells, and cells were treated with selective NR-activating ligands (Fig. 3). CAR and PXR activated the PBREM- and XREM-driven positive control reporters as expected (Mäkinen et al., 2002). The constitutively active CAR enhanced the activity of ALDH1A7 promoter from the RR strain by ∼55-fold, and its ligand TCPOBOP further elevated the reporter activity over 80-fold compared with the pGL3-Basic control reporter, whereas the response to PCN-activated PXR was more modest, ∼16-fold increase; however, the ALDH1A7 promoter from the rr strain was not appreciably affected by CAR or PXR. These findings correlate well with induction of ALDH1A7 mRNA (Fig. 1A) and indicate that the 10-kbp ALDH1A7 RR promoter sequence harbors CAR- and PXR-responsive elements, whereas the rr promoter cannot be activated by these NRs.

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Strain-dependent activation of ALDH1A7 promoter constructs by NRs. Luciferase activity of the full-length RR-ALDH1A7 (gray columns) and rr-ALDH1A7 (black columns) constructs cotransfected with empty (−) or indicated CAR or PXR expression vectors (+), and treated with DMSO (ligand −) or selective CAR or PXR activators (ligand +). Positive control plasmids were PBREM-tk-luc for CAR and XREM-3A4-luc for PXR (white columns). Data are means ± S.D. from three independent transfections and expressed relative to the empty vector (set at 1.0). *Denotes a statistically significant difference from the empty vector at P < 0.05.

Activity of the Proximal ALDH1A7 Promoters from RR and rr Rats.

Because of the low ALDH1A7 expression in the rr strain, we turned our attention next to the proximal ALDH1A7 promoter that contained several TF-binding sites, likely important for the constitutive activity, and the 16-bp deletion in the rr promoter. We measured the reporter activity and responsiveness to NRs of two proximal promoter fragments from both strains. Figure 4A shows that the longer (−1571/+5 bp)) RR fragment conferred a reporter activity of 12.5-fold over the promoterless control construct. Deletion to shorter RR fragment (−461/+5 bp) yielded an activity of about 30% of the longer fragment. The corresponding ALDH1A7 fragments from the rr strain had much weaker activities that tended to be on par or marginally above the pGL3-Basic construct. This finding indicates that the proximal ALDH1A7 promoter (−444/+5 bp) in the rr strain contains defects that reduced the promoter activity and presumably decreased the expression of ALDH1A7 gene.

Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

Basal and NR-elicited activation of proximal ALDH1A7 promoter constructs. (A) Basal luciferase reporter activity from RR-ALDH1A7 and rr-ALDH1A7 longer (−1571/+5 bp) and shorter (−461/+5 bp) promoter fragments. #Denotes a statistically significant different from the pGL3-Basic construct at P < 0.05; (B) NR-dependent luciferase activity from RR-ALDH1A7 and rr-ALDH1A7 longer and shorter promoter fragments in cotransfection assays with empty or indicated NR expression vectors. ns, no statistically significant differences between constructs with empty or NR expression vectors.

Figure 4B shows results from the cotransfection assays with NR expression vectors and the proximal ALDH1A7 fragments. In contrast to the 10-kbp RR promoter (Fig. 3), the more proximal fragments (RR −1571/+5 bp; rr −1556/+5 bp, or shorter) from either rat strain were not activated by ligand-activated CAR or PXR. This result indicates that the CAR/PXR-responsive element(s) lie in the far-upstream region of ALDH1A7.

Binding of Transcriptional Regulators to the ALDH1A7 Promoter Sequences.

To shed more light on the differential expression of ALDH1A7 between RR and rr rats, we studied the binding of RNA polymerase II, an essential factor for RNA transcription, to the proximal ALDH1A7 promoter and binding of NRs to the upstream regions. To this end, we used the ChIP assay with chromatin samples extracted from both strains exposed to vehicle or PB.

We detected significant RNA polymerase II binding (>6-fold over background) to the proximal promoter region (−209/−12 bp) in samples from control RR rats. This binding was clearly elevated by PB (Fig. 5). In contrast, RNA polymerase II showed weak or no binding to the corresponding fragment (−194/−12 bp) from rr rats, regardless of treatment. This finding provides strong support to our hypothesis that the ALDH1A7 gene has an active and PB-responsive promoter in RR rats, whereas its activity is low and noninducible in the rr strain.

Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

Polymerase II binding to RR-ALDH1A7 and rr-ALDH1A7 proximal promoters. Both strains were dosed with saline (C) or PB for 3 hours; liver nuclear fractions were isolated and crosslinked, and RNA polymerase-associated DNA was analyzed by ChIP assay as detailed in Materials and Methods. The amount of recovered DNA is shown relative to the negative control (nc) region (set at 1.0). Data are scatter plots from two independent experiments, each sample with two technical replicates.

Next, we sought to identify the locations of the CAR binding sites in the ALDH1A7 far-upstream region. Because the available CAR antibody was not suitable for ChIP assays, we used instead an antibody to RXRα, the obligate heterodimer partner of CAR and PXR for DNA binding (Honkakoski and Negishi, 2000). A similar approach of using RXRα as a surrogate for CAR binding was taken in previous studies (Saito et al., 2013; Ohno et al., 2014). Inspection of NR binding sites with direct or everted repeats of AGGTCA-like motifs with the NUBIScan algorithm (Podvinec et al., 2002) revealed three putative CAR/RXRα binding sites at −3075 (named CAR1), at −3331 (named CAR2) and at −5202 (named CAR3) for the RR strain (the respective locations are −2907, −3167, and −5046 for the rr strain). Sequence comparison of these sites between the RR and rr strains showed no major differences, apart from a single point mutation in the CAR-RXRα binding CAR1 site (a DR4 element). There were also three other putative CAR/RXRα binding sites (upstream from −8300 in RR); however, they have shown no significant ChIP binding (data not shown).

In Fig. 6A, binding of RXRα was detectable to all three CAR/RXRα binding sites in chromatin samples isolated from control RR rats. Exposure to PB substantially enhanced RXRα binding to CAR1 and CAR2 sites (5- and 10-fold, respectively), whereas the increase was lower at the CAR3 site (2-fold). Experiments performed with chromatin from the rr rats (Fig. 6B) showed low binding both in control and PB-treated samples.

Fig. 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 6.

RXRα binding to putative CAR binding sites in the distal regions of RR-ALDH1A7 (A) and rr-ALDH1A7 (B) promoters. Both strains were dosed with saline (C) or PB for 3 hours, and liver nuclear fractions were isolated and crosslinked, and RXRα- associated DNA was analyzed by ChIP assay as detailed in Materials and Methods. The amount of recovered DNA is shown relative to the negative control region (set at 1.0). Data are scatter plots from two independent experiments, each sample with two technical replicates.

Discussion

The present study provides evidence for the molecular basis underlying the differences in PB inducibility of ALDH activity observed in RR and rr rat strains. We showed that the low ALDH activity in the nonresponsive rr strain is associated with the lack of ALDH protein and mRNA expression. This difference cannot be attributed to defects in the PB induction process itself because expression of the CAR regulator and inducibility of the ALDH1A1, CYP2B1, and CYP3A23 mRNAs were comparable in the two strains. We also showed, for the first time, that the rat ALDH1A7 gene is regulated by PXR and its ligand, albeit to a lesser extent than by CAR.

Reporter gene assays using ALDH1A7 promoter fragments indicated that whereas the largest (10-kbp) fragment from the RR rats was strongly activated by CAR and PXR, the corresponding rr fragment was practically inactive. Other experiments indicated that the proximal rr promoter is clearly weak and cannot recruit RNA polymerase as efficiently as the RR promoter. Apart from a few dispersed point mutations and deletions at positions that did not seem to affect any predicted TF binding site, there is a 16-bp RR sequence at −50/−34 bp, very close to the predicted TATA box, that is lacking in rr rats. This 16-bp sequence is quite similar to a recognition element of the general transcription factor TFIIB (Littlefield et al., 1999), and this site is essential for recruitment of the RNA polymerase II. Accordingly, RNA polymerase II failed to bind to the fragment −194/−12 bp in chromatin samples from the rr rats. Based on the present findings, we suggest that the 16-bp deletion is the ultimate reason for the low ALDH1A7 activity and inducibility by PB in the nonresponsive rr rats.

Upstream regions at −3050 and −3300 bp harbored sites capable of NR binding as indicated by efficient recruitment of RXRα, which is essential for the CAR-dependent transcription. Whereas robust RXRα binding to the RR gene took place especially after PB administration, binding to the rr gene was detected only at low levels and not affected by PB. This is quite surprising given the fact that the NR binding sites in the rr gene were intact. This finding suggests that CAR binding to these distal sites may require priming, that is, appropriate recruitment of factors binding to the proximal ALDH1A7 promoter before CAR binding can occur. This implies that the inability of the proximal ALDH1A7 rr promoter to recruit general TFs may also result in reversion of distal CAR binding sites into a transcriptionally inactive state in the rr rats. There is similar evidence that mutations in a single regulatory sequence can affect the accessibility to TFs of the entire gene locus (Kumasaka et al., 2016).

The genome-wide chromatin accessibility and inducibility by TCPOBOP have recently been investigated in mice. The Cyp2b10 and Aldh1a7 genes belong to a group termed pattern 1, where TCPOBOP produces stronger induction than PCN (Cui and Klaassen, 2016). In the Cyp2b10 gene upstream sequence, there is low but detectable CAR/RXR binding in control animals that is enhanced by 6- to 8-fold after TCPOBOP exposure (Tian et al., 2018). These data correlate well with our findings on the RR ALDH1A7 gene. The murine Aldh1a7 locus contains an active promoter, as evidenced by activating histone H3K4me3 and H3K27Ac marks (Sugathan and Waxman, 2013) and a TCPOBOP-responsive DNase I hypersensitive site (Lodato et al., 2018) overlapping the TSS, a finding that matches well with the active rat ALDH1A7 proximal promoter in RR rats. The far-upstream DNase I hypersensitive sites are located at ∼17 and ∼29 kbp upstream of the Aldh1a7 TSS but still within the same topologically associated domain (Lodato et al., 2018).

In contrast, information on genome chromatin accessibility or epigenetics in the rat liver is quite sparse. The available data [https://www.ebi.ac.uk/arrayexpress: accession number E-MTAB-2663] show that the rat ALDH1A1 gene possesses strong activating histone marks (H3K4me3 and H3K27Ac) that overlap the ALDH1A1 TSS and the first exon (Villar et al., 2015). The co-occurrence of these two histone modifications is indicative of an active promoter, in line with a robust ALDH1A1 mRNA expression in both rr and RR strains; however, in the same data set, coinciding H3K4me3 and H3K27Ac marks closest to the ALDH1A7 gene are more than 200 kbp away from its TSS, which correlates with the low expression of ALDH1A7 mRNA. It should be noted again that the rat reference genome (Rnor 5.0) used in these studies contains the rr strain ALDH1A7 sequence.

Collectively, our results show that PB induces ALDH1A7 expression at activity, protein, and mRNA level in only the responsive RR rats via binding of CAR to upstream elements in ALDH1A7, which is inherently associated with enhanced recruitment of RNA polymerase II to the proximal promoter. Because of sequence variation between these rat strains, the expression and accumulation of ALDH1A7 mRNA are disrupted in the nonresponsive rr rats, which likely also affects ALDH1A7-inducing signals other than PB that act via transcriptional activation.

The human relevance of our findings is still unclear. ALDH1A7 is not present in the human genome as it is thought to be a rodent-specific duplication of the ancestral ALDH1A1 gene. There are no direct publications on PB inducibility of human ALDH1A1, whereas rodent ALDH1A1 and 1A7 genes are both activated. We found an RNA sequencing data set of human HepaRG cells exposed to human CAR- and PXR-activating CITCO and PB (Li et al., 2015; GeoExpress GSE71446) that showed a substantial 3.5- to 16-fold increase in CYP2B6 and CYP3A4 mRNAs but only a slight increase (<40%) in ALDH1A1 mRNA expression.

In conclusion, we consider that the present data have shed light on the 40-year conundrum of strain differences in ALDH inducibility by PB. They also suggest that metabolism of endogenous and exogenous aldehydes may be attenuated in rat strains harboring this genetic defect, which could have consequences for the design and interpretation of biologic, pharmacological and toxicological studies on functions and disposition of aldehydes.

Acknowledgments

We thank Ms. Lea Pirskanen for her expert help in molecular biology assays.

Authorship Contributions

Participated in research design: Touloupi, Küblbeck, Magklara, Molnár, Reinisalo, Honkakoski, Pappas.

Conducted experiments: Touloupi, Küblbeck, Molnár, Reinisalo, Konstandi, Pappas.

Performed data analysis: Touloupi, Küblbeck, Magklara, Reinisalo, Honkakoski, Pappas.

Wrote or contributed to the writing of the manuscript: Touloupi, Magklara, Honkakoski, Pappas.

Footnotes

    • Received May 30, 2019.
    • Accepted September 6, 2019.
  • This work was supported by the Greek Ministry of Education, Research and Religious Affairs-Herakleitos (K.T., A.M., M.K., P.P.) and by the Academy of Finland (J.K, F.M., M.R., P.H). This study is dedicated to Prof. Marios Marselos on his discovery of the strain difference and subsequent work on ALDH induction in the Ioannina rat strains. This work was supported by the Greek Ministry of Education, Research and Religious Affairs-Herakleitos (K.T., A.M., M.K., P.P.) and by the Academy of Finland (J.K, F.M., M.R., P.H). The ALDH1A7 promoter sequences have been submitted to the Genbank with accession numbers MK814117 (RR) and MK814118 (rr).

  • https://doi.org/10.1124/mol.119.117424.

  • ↵Embedded ImageThis article has supplemental material available at molpharm.aspetjournals.org.

Abbreviations

ALDH
aldehyde dehydrogenase
bp
base pair
CAR
constitutive androstane receptor
ChIP
chromatin immunoprecipitation
kbp
kilobase pair
NR
nuclear receptor
P450
cytochrome P450
PB
phenobarbital
PCN
pregnenolone 16α-carbonitrile
PXR
pregnane X receptor
RT-PCR
reverse transcription-polymerase chain reaction
RU486
mifepristone
RXR
retinoid X receptor
SDS
sodium dodecyl sulfate
TCPOBOP
1,4-bis[(3,5-dichloropyridyloxy)]benzene
TF
transcription factor
TSS
transcription start site
  • Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Aleksunes LM and
    2. Klaassen CD
    (2012) Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARα-, and Nrf2-null mice. Drug Metab Dispos 40:1366–1379.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Alnouti Y and
    2. Klaassen CD
    (2008) Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice. Toxicol Sci 101:51–64.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Chai X,
    2. Zeng S, and
    3. Xie W
    (2013) Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond. Expert Opin Drug Metab Toxicol 9:253–266.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Cui JY and
    2. Klaassen CD
    (2016) RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome. Biochim Biophys Acta 1859:1198–1217.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Deitrich RA
    (1971) Genetic aspects of increase in rat liver aldehyde dehydrogenase induced by phenobarbital. Science 173:334–336.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Dunn TJ,
    2. Koleske AJ,
    3. Lindahl R, and
    4. Pitot HC
    (1989) Phenobarbital-inducible aldehyde dehydrogenase in the rat. cDNA sequence and regulation of the mRNA by phenobarbital in responsive rats. J Biol Chem 264:13057–13065.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Goodwin B,
    2. Hodgson E, and
    3. Liddle C
    (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329–1339.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Honkakoski P,
    2. Jääskeläinen I,
    3. Kortelahti M, and
    4. Urtti A
    (2001) A novel drug-regulated gene expression system based on the nuclear receptor constitutive androstane receptor (CAR). Pharm Res 18:146–150.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Honkakoski P,
    2. Moore R,
    3. Gynther J, and
    4. Negishi M
    (1996) Characterization of phenobarbital-inducible mouse Cyp2b10 gene transcription in primary hepatocytes. J Biol Chem 271:9746–9753.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Honkakoski P and
    2. Negishi M
    (2000) Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 347:321–337.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Hsu LC,
    2. Chang WC,
    3. Hoffmann I, and
    4. Duester G
    (1999) Molecular analysis of two closely related mouse aldehyde dehydrogenase genes: identification of a role for Aldh1, but not Aldh-pb, in the biosynthesis of retinoic acid. Biochem J 339:387–395.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Jackson B,
    2. Brocker C,
    3. Thompson DC,
    4. Black W,
    5. Vasiliou K,
    6. Nebert DW, and
    7. Vasiliou V
    (2011) Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum Genomics 5:283–303.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Kathmann EC,
    2. Naylor S, and
    3. Lipsky JJ
    (2000) Rat liver constitutive and phenobarbital-inducible cytosolic aldehyde dehydrogenases are highly homologous proteins that function as distinct isozymes. Biochemistry 39:11170–11176.
    OpenUrl
  14. ↵
    1. Küblbeck J,
    2. Jyrkkärinne J,
    3. Poso A,
    4. Turpeinen M,
    5. Sippl W,
    6. Honkakoski P, and
    7. Windshügel B
    (2008) Discovery of substituted sulfonamides and thiazolidin-4-one derivatives as agonists of human constitutive androstane receptor. Biochem Pharmacol 76:1288–1297.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Kumasaka N,
    2. Knights AJ, and
    3. Gaffney DJ
    (2016) Fine-mapping cellular QTLs with RASQUAL and ATAC-seq. Nat Genet 48:206–213.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Li D,
    2. Mackowiak B,
    3. Brayman TG,
    4. Mitchell M,
    5. Zhang L,
    6. Huang SM, and
    7. Wang H
    (2015) Genome-wide analysis of human constitutive androstane receptor (CAR) transcriptome in wild-type and CAR-knockout HepaRG cells. Biochem Pharmacol 98:190–202.
    OpenUrl
  17. ↵
    1. Lindahl R
    (1992) Aldehyde dehydrogenases and their role in carcinogenesis. Crit Rev Biochem Mol Biol 27:283–335.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Littlefield O,
    2. Korkhin Y, and
    3. Sigler PB
    (1999) The structural basis for the oriented assembly of a TBP/TFB/promoter complex. Proc Natl Acad Sci USA 96:13668–13673.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Lodato NJ,
    2. Rampersaud A, and
    3. Waxman DJ
    (2018) Impact of CAR agonist ligand TCPOBOP on mouse liver chromatin accessibility. Toxicol Sci 164:115–128.
    OpenUrl
  20. ↵
    1. Lowry OH,
    2. Rosebrough NJ,
    3. Farr AL, and
    4. Randall RJ
    (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275.
    OpenUrlFREE Full Text
  21. ↵
    1. Magklara A and
    2. Smith CL
    (2009) A composite intronic element directs dynamic binding of the progesterone receptor and GATA-2. Mol Endocrinol 23:61–73.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Mäkinen J,
    2. Frank C,
    3. Jyrkkärinne J,
    4. Gynther J,
    5. Carlberg C, and
    6. Honkakoski P
    (2002) Modulation of mouse and human phenobarbital-responsive enhancer module by nuclear receptors. Mol Pharmacol 62:366–378.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Marselos M
    (1976) Genetic variation of drug-metabolizing enzymes in the wistar rat. Acta Pharmacol Toxicol (Copenh) 39:186–197.
    OpenUrlPubMed
  24. ↵
    1. Marselos M,
    2. Strom SC, and
    3. Michalopoulos G
    (1987) Effect of phenobarbital and 3-methylcholanthrene on aldehyde dehydrogenase activity in cultures of HepG2 cells and normal human hepatocytes. Chem Biol Interact 62:75–88.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Müller PY,
    2. Janovjak H,
    3. Miserez AR, and
    4. Dobbie Z
    (2002) Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 32:1372–1374, 1376, 1378–1379.
    OpenUrlPubMed
  26. ↵
    1. Ohno M,
    2. Kanayama T,
    3. Moore R,
    4. Ray M, and
    5. Negishi M
    (2014) The roles of co-chaperone CCRP/DNAJC7 in Cyp2b10 gene activation and steatosis development in mouse livers. PLoS One 9:e115663.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Pappas P,
    2. Stephanou P,
    3. Karamanakos P,
    4. Vasiliou V, and
    5. Marselos M
    (2001) Phenobarbital inducibility and differences in protein expression of an animal model. Chem Biol Interact 130–132:275–283.
    OpenUrl
  28. ↵
    1. Pappas P,
    2. Stephanou P,
    3. Vasiliou V, and
    4. Marselos M
    (1998) Zoxazolamine-induced paralysis in two rat substrains: differences in hepatic drug metabolism. Eur J Drug Metab Pharmacokinet 23:461–467.
    OpenUrlPubMed
  29. ↵
    1. Podvinec M,
    2. Kaufmann MR,
    3. Handschin C, and
    4. Meyer UA
    (2002) NUBIScan, an in silico approach for prediction of nuclear receptor response elements. Mol Endocrinol 16:1269–1279.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Saito K,
    2. Moore R, and
    3. Negishi M
    (2013) Nuclear receptor CAR specifically activates the two-pore K+ channel Kcnk1 gene in male mouse livers, which attenuates phenobarbital-induced hepatic hyperplasia. Toxicol Sci 132:151–161.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Sophos NA,
    2. Pappa A,
    3. Ziegler TL, and
    4. Vasiliou V
    (2001) Aldehyde dehydrogenase gene superfamily: the 2000 update. Chem Biol Interact 130–132:323–337.
    OpenUrlCrossRef
  32. ↵
    1. Stanley LA,
    2. Horsburgh BC,
    3. Ross J,
    4. Scheer N, and
    5. Wolf CR
    (2006) PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 38:515–597.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Sugathan A and
    2. Waxman DJ
    (2013) Genome-wide analysis of chromatin states reveals distinct mechanisms of sex-dependent gene regulation in male and female mouse liver. Mol Cell Biol 33:3594–3610.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Tian J,
    2. Marino R,
    3. Johnson C, and
    4. Locker J
    (2018) Binding of drug-activated CAR/Nr1i3 alters metabolic regulation in the liver. iScience 9:209–228.
    OpenUrl
  35. ↵
    1. Vasiliou V and
    2. Marselos M
    (1989) Tissue distribution of inducible aldehyde dehydrogenase activity in the rat after treatment with phenobarbital or methylcholanthrene. Pharmacol Toxicol 64:39–42.
    OpenUrlPubMed
  36. ↵
    1. Villar D,
    2. Berthelot C,
    3. Aldridge S,
    4. Rayner TF,
    5. Lukk M,
    6. Pignatelli M,
    7. Park TJ,
    8. Deaville R,
    9. Erichsen JT,
    10. Jasinska AJ, et al.
    (2015) Enhancer evolution across 20 mammalian species. Cell 160:554–566.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Westerlund M,
    2. Galter D,
    3. Carmine A, and
    4. Olson L
    (2005) Tissue- and species-specific expression patterns of class I, III, and IV Adh and Aldh 1 mRNAs in rodent embryos. Cell Tissue Res 322:227–236.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 96 (5)
Molecular Pharmacology
Vol. 96, Issue 5
1 Nov 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Basis for Strain-Dependent Rat Aldehyde Dehydrogenase 1A7 (ALDH1A7) Gene Expression
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Strain-Dependent ALDH1A7 Expression in the Rat

Katerina Touloupi, Jenni Küblbeck, Angeliki Magklara, Ferdinand Molnár, Mika Reinisalo, Maria Konstandi, Paavo Honkakoski and Periklis Pappas
Molecular Pharmacology November 1, 2019, 96 (5) 655-663; DOI: https://doi.org/10.1124/mol.119.117424

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Strain-Dependent ALDH1A7 Expression in the Rat

Katerina Touloupi, Jenni Küblbeck, Angeliki Magklara, Ferdinand Molnár, Mika Reinisalo, Maria Konstandi, Paavo Honkakoski and Periklis Pappas
Molecular Pharmacology November 1, 2019, 96 (5) 655-663; DOI: https://doi.org/10.1124/mol.119.117424
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics